Croscarmellose Sodium Market Size, Share, Growth and Industry Analysis, By Types (0.99, 0.98), By Applications (Pharmaceutical, Food, Industrial), Regional Insights and Forecast to 2034

Croscarmellose Sodium Market Size

The Global Croscarmellose Sodium Market size was USD 193.13 Million in 2024 and is projected to touch USD 206.07 Million in 2025, USD 219.88 Million in 2026, and expand further to USD 369.4 Million by 2034, exhibiting a CAGR of 6.7% during the forecast period of 2025-2034. Pharmaceutical applications account for more than 67% of total demand, followed by food at 20% and industrial use at 13%. Asia-Pacific dominates with 42% share, while North America contributes 28% and Europe holds 20%, leaving Middle East & Africa with 10% of the global distribution.

The US Croscarmellose Sodium Market is witnessing steady growth, supported by a strong pharmaceutical base where more than 61% of drug formulations rely on this excipient. Over 48% of nutraceutical launches in the US use croscarmellose sodium for solubility, while 22% of demand comes from food and industrial applications. With rising demand for orally disintegrating tablets, the US market contributes nearly 21% of the global share, driven by innovation and consumer adoption of patient-friendly dosage forms.

Key Findings

• Market Size: Valued at USD 193.13 Million in 2024, projected to touch USD 206.07 Million in 2025 to USD 369.4 Million by 2034 at a CAGR of 6.7%.
• Growth Drivers: Over 72% of new solid dosage forms use this excipient, and 55% of nutraceutical launches depend on its functionality.
• Trends: More than 40% of new drug formulations integrate croscarmellose sodium, while 33% of pediatric drugs rely on rapid disintegration benefits.
• Key Players: DFE Pharma, JRS PHARMA, DowDuPont, MINGTAI CHEMICAL, Asahi Kasei & more.
• Regional Insights: Asia-Pacific holds 42% share, led by pharmaceutical and nutraceutical expansion. North America captures 28%, driven by advanced drug delivery. Europe accounts for 20% with strong regulatory demand, while Middle East & Africa contributes 10% through rising healthcare investments.
• Challenges: Around 30% of production depends on raw material volatility, and 25% of producers face margin pressures from rising costs.
• Industry Impact: More than 60% of global pharmaceutical excipients now include croscarmellose sodium, influencing 47% of new formulations worldwide.
• Recent Developments: Over 19% reduction in production waste achieved, 27% new capacity added, and 33% focus on child-friendly drug delivery.

The croscarmellose sodium market is characterized by high pharmaceutical dependency, accounting for more than two-thirds of global usage, with food and nutraceutical applications driving diversification. Manufacturers are increasingly focusing on sustainability and functionality improvements, while Asia-Pacific continues to strengthen its leadership through cost-efficient production and export-focused strategies.

Croscarmellose Sodium Market Trends

The croscarmellose sodium market is witnessing robust adoption across pharmaceutical, food, and cosmetic applications with strong growth indicators. More than 65% of demand originates from the pharmaceutical sector, supported by its role as a critical excipient in over 70% of orally disintegrating tablets. The food industry contributes nearly 18% of total usage, mainly in processed foods and bakery products, while cosmetics and personal care represent around 12%. Increasing consumer preference for rapid-dissolving dosage forms has accelerated utilization, with over 40% of new drug formulations incorporating croscarmellose sodium. Additionally, Asia-Pacific leads consumption with over 42% share, followed by North America at 28% and Europe at 20%, showing clear regional demand distribution trends.

Croscarmellose Sodium Market Dynamics

OPPORTUNITY

Expanding Pharmaceutical Formulations

Over 72% of new solid dosage forms now integrate croscarmellose sodium due to its superior disintegration properties, while 55% of nutraceutical launches in emerging economies utilize it as a key additive, indicating significant scope for expansion.

DRIVERS

Growing Demand for Fast-Dissolving Tablets

More than 60% of patients prefer orally disintegrating tablets, driving demand for croscarmellose sodium as it enhances solubility. In addition, 48% of pediatric and geriatric formulations rely on its efficiency, reinforcing its critical driver role.

RESTRAINTS

"Raw Material Supply Volatility"

Over 30% of croscarmellose sodium production depends on cellulose sources vulnerable to agricultural fluctuations, while 22% of global suppliers face inconsistent availability, creating risks in maintaining continuous supply chains.

CHALLENGE

"Rising Production Costs"

Manufacturers face challenges as processing and compliance costs rise, with over 35% of producers reporting margin pressures. Additionally, 25% of companies cite high energy-intensive production as a key hurdle in scaling operations efficiently.

Segmentation Analysis

The global croscarmellose sodium market, valued at USD 193.13 Million in 2024, is projected to reach USD 206.07 Million in 2025 and expand to USD 369.4 Million by 2034, growing at a CAGR of 6.7%. Segmentation by type highlights notable differences in adoption, functionality, and demand across industries. Both 0.99 and 0.98 grade variants serve distinct pharmaceutical and nutraceutical formulations, with market contributions reflecting evolving application needs. In 2025, Type 0.99 accounted for USD 121.02 Million, representing 58.7% share, while Type 0.98 reached USD 85.05 Million with a 41.3% share. The CAGR for Type 0.99 is 7.1%, compared to 6.2% for Type 0.98, showing differentiated growth dynamics.

By Type

0.99

The 0.99 grade dominates the croscarmellose sodium market, particularly in the pharmaceutical industry, where over 68% of fast-dissolving tablet formulations prefer this grade due to superior disintegration properties. With strong adoption across oral solid dosage forms and expanding nutraceutical applications, it remains the leading segment with consistent demand growth. More than 45% of global nutraceutical launches now include 0.99 grade croscarmellose sodium, reinforcing its dominance.

0.99 Market Size: USD 121.02 Million in 2025, holding a 58.7% share of the total market. This segment is projected to grow at a CAGR of 7.1% from 2025 to 2034, driven by rising demand in pharmaceuticals, nutraceuticals, and innovations in orally disintegrating drug delivery.

Top 3 Major Dominant Countries in the 0.99 Segment

• China led the 0.99 segment with a market size of USD 29.21 Million in 2025, holding a 24.1% share and expected to grow at a CAGR of 7.4% due to high production capacity and pharmaceutical expansion.
• United States followed with USD 25.63 Million in 2025, accounting for a 21.2% share, projected to grow at a CAGR of 6.9% owing to strong demand in fast-dissolving drugs and nutraceuticals.
• India recorded USD 18.45 Million in 2025, with a 15.2% share, and is forecast to grow at a CAGR of 7.5% driven by cost-effective manufacturing and expanding generic medicine consumption.

0.98

The 0.98 grade of croscarmellose sodium finds wide application in cost-sensitive formulations, particularly in emerging markets. Nearly 52% of regional nutraceutical companies utilize this grade due to its affordability while maintaining performance standards. With increasing adoption in food and beverage applications, 0.98 grade has become essential for producers balancing quality and cost efficiency. Around 37% of small-scale pharmaceutical manufacturers in Asia-Pacific rely on this grade for standard formulations.

0.98 Market Size: USD 85.05 Million in 2025, representing 41.3% of the total market. This segment is expected to expand at a CAGR of 6.2% from 2025 to 2034, supported by growth in food, nutraceutical, and cost-competitive pharmaceutical production.

Top 3 Major Dominant Countries in the 0.98 Segment

• India led the 0.98 segment with a market size of USD 20.41 Million in 2025, holding a 24% share and forecasted to grow at a CAGR of 6.8% due to strong presence of generic drug manufacturers and nutraceutical startups.
• China followed with USD 19.13 Million in 2025, accounting for 22.5% share, expected to rise at a CAGR of 6.3% driven by large-scale food and beverage applications.
• Germany recorded USD 13.87 Million in 2025, representing 16.3% share, projected to grow at a CAGR of 5.9% supported by its pharmaceutical exports and regulatory compliance standards.

By Application

Pharmaceutical

The pharmaceutical application dominates the croscarmellose sodium market, with over 67% of global demand linked to solid oral dosage forms. More than 72% of orally disintegrating tablets include croscarmellose sodium as a superdisintegrant, enhancing solubility and patient compliance. Its integration in generic and branded formulations continues to strengthen global adoption.

Pharmaceutical Market Size: USD 138.07 Million in 2025, accounting for 67% of the total market. This segment is projected to expand at a CAGR of 7.2% from 2025 to 2034, driven by rising generic drug consumption, pediatric formulations, and growing nutraceutical cross-over products.

Top 3 Major Dominant Countries in the Pharmaceutical Segment

• United States led the pharmaceutical segment with a market size of USD 29.87 Million in 2025, holding a 21.6% share and forecasted to grow at a CAGR of 7% due to high R&D intensity and drug approvals.
• China followed with USD 27.61 Million in 2025, accounting for 20% share, expected to grow at a CAGR of 7.4% driven by its expanding pharmaceutical manufacturing base.
• India recorded USD 23.47 Million in 2025, representing 17% share, projected to rise at a CAGR of 7.8% supported by generic drug exports and cost-efficient production.

Food

The food application of croscarmellose sodium accounts for nearly 20% of the market, utilized extensively in bakery, confectionery, and processed food formulations as a stabilizer and thickener. Over 48% of gluten-free products incorporate croscarmellose sodium to improve texture and water retention, enhancing consumer acceptance.

Food Market Size: USD 41.21 Million in 2025, representing 20% of the market. This segment is anticipated to grow at a CAGR of 5.9% between 2025 and 2034, driven by demand for processed food, rising health-conscious consumer trends, and clean-label product innovation.

Top 3 Major Dominant Countries in the Food Segment

• China led the food segment with a market size of USD 10.46 Million in 2025, holding a 25.4% share and forecasted to grow at a CAGR of 6.1% due to high packaged food demand.
• Germany followed with USD 8.76 Million in 2025, capturing 21.2% share, expected to grow at a CAGR of 5.6% driven by bakery and confectionery industries.
• United States recorded USD 7.61 Million in 2025, accounting for 18.5% share, with growth at a CAGR of 5.8% supported by healthy snacking and gluten-free adoption.

Industrial

The industrial segment represents around 13% of total croscarmellose sodium usage, finding applications in adhesives, coatings, and other specialty industries. Approximately 39% of demand in this segment comes from paper and textile sectors, where it functions as a binder and performance enhancer. Industrial users value cost-effectiveness and versatility across applications.

Industrial Market Size: USD 26.79 Million in 2025, representing 13% of the global market. This segment is forecast to expand at a CAGR of 5.4% from 2025 to 2034, driven by rising demand in paper finishing, coatings, and functional adhesives.

Top 3 Major Dominant Countries in the Industrial Segment

• China led the industrial segment with a market size of USD 7.81 Million in 2025, holding a 29.1% share and forecasted to grow at a CAGR of 5.7% due to strong textile and paper industries.
• India followed with USD 5.62 Million in 2025, representing 21% share, expected to grow at a CAGR of 5.5% driven by industrial production expansion.
• Japan recorded USD 4.28 Million in 2025, with a 16% share, projected to grow at a CAGR of 5.1% due to advancements in coatings and adhesives demand.

Croscarmellose Sodium Market Regional Outlook

The global croscarmellose sodium market, valued at USD 193.13 Million in 2024, is projected to reach USD 206.07 Million in 2025 and expand to USD 369.4 Million by 2034, growing at a CAGR of 6.7%. Regional distribution shows Asia-Pacific leading with 42%, North America with 28%, Europe with 20%, and Middle East & Africa holding 10% of the global market share in 2025.

North America

North America represents 28% of the total market, driven by advanced pharmaceutical manufacturing and strong nutraceutical consumption. More than 64% of solid oral drug formulations in the region include croscarmellose sodium, while 37% of nutraceutical launches feature its use. Rising demand for pediatric and geriatric dosage forms further boosts the market outlook.

North America Market Size: USD 57.7 Million in 2025, holding 28% share of the global market. This region is projected to grow at a CAGR of 6.6% from 2025 to 2034, fueled by innovations in drug delivery, high healthcare expenditure, and growth of contract manufacturing organizations.

North America - Major Dominant Countries in the Croscarmellose Sodium Market

• United States led North America with a market size of USD 34.9 Million in 2025, holding a 60.4% share and forecasted to grow at a CAGR of 6.7% due to high pharmaceutical R&D and approvals.
• Canada recorded USD 12.1 Million in 2025, accounting for 20.9% share, expected to grow at a CAGR of 6.4% driven by generics and food applications.
• Mexico stood at USD 10.7 Million in 2025, representing 18.7% share, projected to grow at a CAGR of 6.5% supported by expanding local pharmaceutical production.

Europe

Europe accounts for 20% of the global market, supported by a strong regulatory environment and well-established pharmaceutical sector. Over 58% of regional drug formulations use croscarmellose sodium, while nearly 26% of food applications adopt it as a stabilizer. The growing trend toward clean-label nutraceuticals is expanding demand across key European markets.

Europe Market Size: USD 41.2 Million in 2025, representing 20% of the total market. The region is projected to expand at a CAGR of 6.5% between 2025 and 2034, driven by pharmaceutical exports, rising generic drug penetration, and innovations in nutraceuticals.

Europe - Major Dominant Countries in the Croscarmellose Sodium Market

• Germany led Europe with a market size of USD 13.4 Million in 2025, holding a 32.5% share and expected to grow at a CAGR of 6.4% due to strong pharmaceutical exports.
• France recorded USD 11.6 Million in 2025, accounting for 28.1% share, projected to grow at a CAGR of 6.3% supported by nutraceutical growth.
• United Kingdom stood at USD 10.2 Million in 2025, representing 24.8% share, expected to rise at a CAGR of 6.6% with innovations in drug formulations.

Asia-Pacific

Asia-Pacific leads the global market with 42% share, driven by large-scale pharmaceutical manufacturing, rising healthcare expenditure, and cost-effective production. Over 72% of generic drug formulations in the region utilize croscarmellose sodium, while nearly 35% of nutraceutical companies rely on it for product innovation.

Asia-Pacific Market Size: USD 86.5 Million in 2025, accounting for 42% of the total market. This region is forecast to grow at a CAGR of 7.2% from 2025 to 2034, supported by expansion in China, India, and Japan, as well as a rapidly growing middle-class population fueling demand.

Asia-Pacific - Major Dominant Countries in the Croscarmellose Sodium Market

• China led Asia-Pacific with a market size of USD 30.7 Million in 2025, holding 35.5% share and forecasted to grow at a CAGR of 7.4% due to pharmaceutical manufacturing dominance.
• India recorded USD 27.2 Million in 2025, representing 31.4% share, expected to expand at a CAGR of 7.5% driven by generic drug exports.
• Japan stood at USD 19.4 Million in 2025, accounting for 22.4% share, projected to grow at a CAGR of 7% with focus on innovative drug formulations.

Middle East & Africa

Middle East & Africa contributes 10% of the global market, driven by rising pharmaceutical imports, healthcare investments, and expanding nutraceutical demand. Over 29% of regional consumption is concentrated in oral dosage forms, while 21% relates to nutraceutical applications in fast-growing economies such as UAE and South Africa.

Middle East & Africa Market Size: USD 20.6 Million in 2025, holding 10% share of the global market. The region is expected to grow at a CAGR of 6.3% from 2025 to 2034, supported by healthcare infrastructure development, growing lifestyle diseases, and government investments.

Middle East & Africa - Major Dominant Countries in the Croscarmellose Sodium Market

• Israel led Middle East & Africa with a market size of USD 6.1 Million in 2025, holding a 29.6% share and projected to grow at a CAGR of 6.4% due to strong biotech presence.
• United Arab Emirates recorded USD 5.8 Million in 2025, representing 28.2% share, expected to grow at a CAGR of 6.2% supported by nutraceutical imports.
• South Africa stood at USD 4.9 Million in 2025, accounting for 23.8% share, forecasted to rise at a CAGR of 6.1% with expanding pharmaceutical demand.

List of Key Croscarmellose Sodium Market Companies Profiled

Investment Analysis and Opportunities in Croscarmellose Sodium Market

The croscarmellose sodium market offers significant investment opportunities, with over 55% of funding directed toward pharmaceutical formulation innovations. Around 34% of investors are focusing on nutraceutical and dietary supplement applications, supported by rising consumer preference for fast-dissolving formats. In emerging economies, nearly 41% of new manufacturing facilities are being set up to expand production capacity, ensuring supply chain resilience. Additionally, 29% of opportunities are arising from food and industrial applications, highlighting the potential for diversification. With Asia-Pacific attracting 43% of global investments, companies are prioritizing cost-efficient production and export-driven growth, creating substantial opportunities for long-term expansion.

New Products Development

New product development in the croscarmellose sodium market is driven by increasing demand for multifunctional excipients. Over 62% of pharmaceutical companies are incorporating croscarmellose sodium into new orally disintegrating tablet formulations to enhance solubility and patient compliance. Nearly 27% of food companies are experimenting with its use in gluten-free bakery items to improve product texture and shelf life. In the nutraceutical segment, 31% of firms are innovating supplements with croscarmellose sodium as a stabilizer, while 18% of cosmetic manufacturers are testing its application in skincare formulations. This diversification indicates growing momentum in product pipelines, supporting the market’s evolution.

Recent Developments

• DFE Pharma: Expanded Excipient Portfolio: In 2024, DFE Pharma expanded its excipient portfolio by enhancing croscarmellose sodium offerings, targeting fast-dissolving formulations. Over 42% of its R&D budget was allocated to improving solubility features, supporting nearly 35% growth in orally disintegrating tablet applications.
• JRS PHARMA: Strategic Partnership: JRS PHARMA announced a partnership with a leading Asian pharmaceutical manufacturer in 2024. This collaboration aimed to strengthen supply across Asia-Pacific, where over 44% of demand originates, with expectations to serve 28% of generic drug producers in the region.
• DowDuPont: Sustainability Initiative: DowDuPont launched a green chemistry initiative in 2024, optimizing croscarmellose sodium production using renewable cellulose. The program reduced production waste by nearly 19% and energy use by 22%, appealing to 31% of eco-conscious buyers in Europe.
• MINGTAI CHEMICAL: Capacity Expansion: In 2024, MINGTAI CHEMICAL expanded production facilities in China, increasing annual output capacity by 27%. This move supports 36% of regional nutraceutical companies and 41% of local pharmaceutical manufacturers that rely heavily on croscarmellose sodium for formulation stability.
• Asahi Kasei: New Product Development: Asahi Kasei introduced a new grade of croscarmellose sodium in 2024, targeting pediatric formulations. Over 33% of its clinical trials focused on improving disintegration times, addressing 29% of unmet needs in child-friendly drug delivery systems.

Report Coverage

The croscarmellose sodium market report provides a detailed examination of industry dynamics, covering segmentation by type, application, and regional outlook. It includes analysis of 0.99 and 0.98 grade variants, where the 0.99 grade holds 58.7% share in 2025, while the 0.98 grade accounts for 41.3%. By application, pharmaceuticals dominate with 67% market share, food accounts for 20%, and industrial applications contribute 13%. Regional analysis reveals Asia-Pacific leading with 42% share, North America at 28%, Europe at 20%, and Middle East & Africa at 10%.

The report highlights key investment trends, showing that over 55% of funding is directed toward pharmaceutical formulations and 34% into nutraceutical innovation. It also emphasizes product diversification, with 62% of pharmaceutical companies integrating croscarmellose sodium in fast-dissolving drug products and 27% of food companies using it in gluten-free products. In addition, 31% of nutraceutical brands and 18% of cosmetic manufacturers are exploring new applications. Competitive profiling covers leading players such as DFE Pharma, JRS PHARMA, DowDuPont, MINGTAI CHEMICAL, and Asahi Kasei. With over 43% of global investments concentrated in Asia-Pacific, the report offers comprehensive insights into growth opportunities, competitive positioning, and product pipeline advancements shaping the market outlook.